Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study ...

- Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC -

Related Keywords

United States ,Guangzhou ,Guangdong ,China ,Shanghai ,Suzhou ,Jiangsu ,Beijing ,Maryland ,Canada ,San Francisco ,California ,Chinese ,Patricia Keegan ,Denny Lanfear ,Toripalimab ,Coherus Biosciences ,Sheng Yao ,Eli Lilly ,Ruihua Xu ,Mcdavid Stilwell ,Junshi Biosciences ,Junshi Biosciences Zhi Li ,Institute Of Microbiology Chinese Academy ,Coherus Biosciences Inc ,Drug Administration ,Junshi Biosciences Contact Information Ir Team ,Sun Yat Sen University Cancer Center ,Nasdaq ,Exchange Commission ,National Reimbursement Drug List ,National Medical Products Administration ,Pr Team ,European Society For Medical Oncology ,Shanghai Junshi Biosciences Co Ltd ,Cancer Cell ,European Society ,Medical Oncology ,Chief Medical Officer ,Senior Vice President ,United States Food ,Orphan Drug Designation ,New Drug Application ,Southeast Asia ,New Drug Applications ,Prescription Drug User Fee Act ,Breakthrough Therapy ,Fast Track ,Junshi Biosciences Founded ,Chinese Academy ,Emergency Use Authorizations ,Looking Statements Except ,Private Securities Litigation Reform Act ,Coheru Annual Report ,Press Release ,Contact Information Investors ,Kelli Perkins Red House ,Money ,Ational ,